Skip to main content
Erschienen in: World Journal of Urology 8/2016

10.06.2016 | Topic Paper

Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome

verfasst von: Bernhard Brehmer, Caroline Kauffmann, Christian Blank, Axel Heidenreich, Axel Bex

Erschienen in: World Journal of Urology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To analyse probability of complete local control and outcome in patients with metastases and local recurrences who have a high probability of failure of local therapy and who were treated with presurgical targeted therapy with the intention to reconsider complete resection or other local therapies such as radiotherapy or ablation.

Method

From two institutional databases, patients with metastatic or locally recurrent RCC were retrospectively identified who received targeted therapy based on a multidisciplinary tumour board decision because of high probability of failure of local control.

Results

From January 2007 until November 2014, 34 patients were treated and included in the analysis. Five patients underwent no local therapy due to insufficient downsizing to attempt resection. The probability of proceeding to local therapy was 85.3 %. Median overall survival of 29 patients with local therapy after pretreatment was 67 months (range 9–173, 95 % CI 90.87) with a median disease-free survival of 12 months (range 0–147 months). The probability to achieve complete local therapy and discontinue targeted therapy was 73.5 % (25 of 34 patients). Median time without systemic therapy was 12 months.

Conclusion

In a retrospective series of patients with a high probability of failure of local therapy, neoadjuvant targeted therapy was associated with successful complete local treatment in approximately 70 % of patients with a time off targeted therapy of ≥1 year in 50 %. Only number of metastatic sites and the disease-free interval after treatment were associated with outcome.
Literatur
2.
Zurück zum Zitat Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, Lundstam S (2014) Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 48(3):231–238. doi:10.3109/21681805.2013.864698 CrossRefPubMed Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, Lundstam S (2014) Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 48(3):231–238. doi:10.​3109/​21681805.​2013.​864698 CrossRefPubMed
3.
Zurück zum Zitat Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int 106(9):1266–1269CrossRefPubMed Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int 106(9):1266–1269CrossRefPubMed
4.
Zurück zum Zitat Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC (2007) Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int 100(4):755–759CrossRefPubMed Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC (2007) Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int 100(4):755–759CrossRefPubMed
5.
Zurück zum Zitat Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A (2014) Local treatments for metastases of renal-cell carcinoma: a systematic review. Lancet Oncol 15(12):e549–e561CrossRefPubMed Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A (2014) Local treatments for metastases of renal-cell carcinoma: a systematic review. Lancet Oncol 15(12):e549–e561CrossRefPubMed
6.
Zurück zum Zitat Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882CrossRef Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882CrossRef
7.
Zurück zum Zitat Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG (2009) Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 181(5):2044–2051CrossRefPubMed Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG (2009) Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 181(5):2044–2051CrossRefPubMed
8.
Zurück zum Zitat Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B (2012) Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 30(5):482–487CrossRefPubMed Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B (2012) Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 30(5):482–487CrossRefPubMed
9.
Zurück zum Zitat Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA (2015) Surgical management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. J Urol 194(2):316–322. doi:10.1016/j.juro.2015.02.2943 CrossRefPubMed Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA (2015) Surgical management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. J Urol 194(2):316–322. doi:10.​1016/​j.​juro.​2015.​02.​2943 CrossRefPubMed
10.
Zurück zum Zitat Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16(6):2261–2266PubMed Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16(6):2261–2266PubMed
11.
Zurück zum Zitat Krishnamurthi V, Novick AC, Bukowski RM (1998) Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51(6):933–937CrossRefPubMed Krishnamurthi V, Novick AC, Bukowski RM (1998) Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51(6):933–937CrossRefPubMed
12.
Zurück zum Zitat Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG (2011) Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 59(1):10–15CrossRefPubMed Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG (2011) Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 59(1):10–15CrossRefPubMed
13.
Zurück zum Zitat Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG (2011) Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60(6):1273–1279CrossRefPubMedPubMedCentral Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG (2011) Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60(6):1273–1279CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180:94–98CrossRefPubMed Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180:94–98CrossRefPubMed
15.
Zurück zum Zitat Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM (2011) Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439–444CrossRefPubMed Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM (2011) Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439–444CrossRefPubMed
16.
Zurück zum Zitat Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS (2008) Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 102(6):692–696CrossRefPubMed Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS (2008) Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 102(6):692–696CrossRefPubMed
17.
Zurück zum Zitat Patard JJ, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S (2009) Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol 55(1):237–239CrossRefPubMed Patard JJ, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S (2009) Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol 55(1):237–239CrossRefPubMed
18.
Zurück zum Zitat O’Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W III, Pili R, Schwaab T (2011) Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology 78(3):595–600CrossRefPubMed O’Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W III, Pili R, Schwaab T (2011) Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology 78(3):595–600CrossRefPubMed
20.
Zurück zum Zitat Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J (2009) Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27(4):533–539CrossRefPubMed Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J (2009) Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27(4):533–539CrossRefPubMed
21.
Zurück zum Zitat Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076–4081CrossRefPubMedPubMedCentral Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076–4081CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A (2013) Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology 81(1):111–115CrossRefPubMed Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A (2013) Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. Urology 81(1):111–115CrossRefPubMed
23.
Zurück zum Zitat Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O’Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A (2011) The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol 60(3):448–454CrossRefPubMed Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O’Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A (2011) The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol 60(3):448–454CrossRefPubMed
Metadaten
Titel
Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome
verfasst von
Bernhard Brehmer
Caroline Kauffmann
Christian Blank
Axel Heidenreich
Axel Bex
Publikationsdatum
10.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 8/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1865-8

Weitere Artikel der Ausgabe 8/2016

World Journal of Urology 8/2016 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.